Nanexa granted patent in China
Nanexa AB (publ) today announced that the company has been granted a patent in China. This primary patent covers the manufacturing method, products that come out of it, and the use of PharmaShell®-coated drugs.
"This is an important milestone that we have worked hard and long for. As our primary patent has now been granted in the important markets of the USA, Japan and China, we have established broad patent protection connected to PharmaShell. I hope that we will be able to receive more patent approvals during the year,” said David Westberg, CEO of Nanexa.
The patent application for the primary patent for the drug delivery system has also been filed in the European Patent Office, Canada, India and South Korea.